WO2002052043A1 - Procede de detection d'un micro-organisme pathogene - Google Patents
Procede de detection d'un micro-organisme pathogene Download PDFInfo
- Publication number
- WO2002052043A1 WO2002052043A1 PCT/JP2001/011422 JP0111422W WO02052043A1 WO 2002052043 A1 WO2002052043 A1 WO 2002052043A1 JP 0111422 W JP0111422 W JP 0111422W WO 02052043 A1 WO02052043 A1 WO 02052043A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- detecting
- probe
- sequence
- nucleic acid
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to an oligonucleotide probe and a primer useful for detecting a pathogenic microorganism, a method for detecting a pathogenic microorganism using them, and a kit for the method.
- Known methods for detecting a pathogenic microorganism include a method of immunologically detecting a protein derived from the microorganism or a method of amplifying and detecting a specific region of a gene derived from the microorganism by a nucleic acid amplification reaction.
- a detection method using a nucleic acid amplification reaction is exemplified.
- the nucleic acid amplification reaction include the polymerase chain reaction (PCR) described in U.S. Patent Nos.
- TAS Transcription ⁇ system
- a nucleic acid amplification method that can be carried out under isothermal conditions has been developed.
- SDA strand displacement amplification
- nucleic acid amplification methods that can be used in the detection of pathogenic microorganisms.
- Various target nucleic acid regions suitable for each nucleic acid amplification reaction are used to satisfy the detection sensitivity required by the actual site for testing actual pathogenic microorganisms. It has been difficult to select primers suitable for the nucleic acid amplification method described above and probes suitable for the target nucleic acid detection method following each nucleic acid amplification reaction.
- a method for detecting pathogenic microorganisms that can obtain reproducible results at low running cost.
- the pathogenic microorganisms will be described by taking, for example, Mycobacterium tuberculosis, Phosphorus bacteria, Chlamydia, and Hepatitis C virus (HCV).
- Tuberculosis has been a leading cause of human death in the past, and there are still a large number of patients today when various therapies are developed.
- the Mycobacterium tuberculosis group includes Mycobacteri um tubercuiosis, Mycobacteri um bovis B CG, My cobacteri um african um, My cobacteri um microti, and My cobacteri um canetti.
- a method for rapidly detecting the presence of Mycobacterium tuberculosis by PCR [Lancet (Lancet), 8 6 ⁇ No. 1, pp. 1069 (1989)] has been reported I have.
- a gene encoding the 65 kDa antigen of Mycobacterium tuberculosis is used as a target, amplified by PCR, and detected by electrophoresis.
- a kit for amplifying 16S liposome RNA and detecting the amplified product with a chemiluminescent probe is also commercially available [Gen-Probe].
- PCR kits targeting DNA encoding 16S liposomal RNA are also commercially available (Roche).
- IS 6110 which is specific to the M. tuberculosis group, has been published [Nucleic Acids Research, Vol. 18, p. 188 (1990)]. It is described that it would be useful as a probe for detection. In fact, a method for detecting the IS 6110 gene by PCR has been reported [J. Clin. Microbiol., Vol. 28, p. 2668 (1990)]. . Since then, many papers on the PCR method targeting the IS6110 gene have been reported, and their usefulness has been described. In addition, there is Japanese Patent No.
- a nucleic acid amplification detection method targeting a ribosomal RNA gene has been widely reported.
- it is intended to amplify a portion common to the genus Mycobacterium and identify a tuberculosis bacterium with a species-specific probe.
- this method it is only the probe sequence that determines the specificity for M. tuberculosis, and there are many cases in which there is anxiety, including the sensitivity of detection, and even culture-positive samples cannot be detected. It has been reported.
- Hybridization is used to detect amplification products.
- the amplified double-stranded nucleic acid is first denatured by strong force in a liquid layer, and then the denatured single-stranded nucleic acid is denatured.
- a method of hybridizing with a probe under neutral conditions in the presence of a stripped complementary nucleic acid was used (Roche Amplicor Kit manual). In this case, there was a problem that the hybridization of the probe was competitively hindered by the complementary amplification nucleic acid peeled off from the double strand, and the sensitivity / specificity did not increase.
- the amplified double-stranded DNA was converted into a single-stranded DNA by alkali denaturation, neutralized, and then hybridized with a probe under neutral conditions.
- thermal denaturation was performed in favor of alkali denaturation, but this made it impossible to accurately test a large number of samples. For this reason, many steps were involved, and one of the single-stranded DNAs competed with the probe and hybridized, resulting in a decrease in target nucleic acid detection sensitivity.
- Phosphorus bacteria ie, Neisseriagonorrhoeae
- Phosphorus bacteria are pathogens of gonorrhea, one of the most commonly reported bacterial infections in the United States. Miyada and Born, 1991, Mol. Cell. Probes 5: 327-335; U.S. Pat. No. 5,256,536; and U.S. Pat. No. 5,525,711 are N. Gonorhoea.
- Cytosine DNA methyl transferase Describes the detection of N. gonorphoea using a DNA probe derived from a genomic fragment containing an open reading frame (ORF 1) with significant homology to the sequence of the M. Ngo II gene are doing. However, there was no method that could specifically detect phosphorus bacteria with sufficient sensitivity.
- Chlamydia refers to a microorganism belonging to the genus Chlamydia.
- Chlamydia trachomatis has been reported to be the most common sexually transmitted disease in developed societies, causing genital infections in both sexes. Therefore, there is a need for methods and reagents that can specifically and timely detect Chlamydia trachomatis.
- RT-PCR reverse transcription PCR
- This method consists of (1) extraction of HCV RNA from serum, (2) synthesis of cDNA using the extracted RNA as type III, (3) amplification by PCR with increasing and decreasing temperature, and (4) immobilized probe. (5) Washing and removal of unreacted reagent, (6) Reaction with labeling reagent, (7) Washing and removal of unreacted reagent, (8) Addition of color-forming reagent, (9) Color-stopping agent (10) Absorbance measurement is performed in a total of 10 steps. Also, HCV detection by a homogenous detection method using a real-time detection PCR method described in J. Virol. Methods Vol. 64, ppl 47-159 (1997) has been studied.
- a main object of the present invention is to provide a means for measuring pathogenic microorganisms for a large number of specimens within a certain period of time with high sensitivity, accuracy, accuracy, convenience, short time, and low cost.
- the present inventors have found a method for detecting a pathogenic microorganism using a nucleic acid amplification method that is superior to conventional nucleic acid amplification methods.
- a chimeric oligonucleotide primer for amplifying a target nucleic acid and a probe for detecting a target nucleic acid for the method have been found.
- a kit for the method was constructed, and the present invention was completed.
- the first invention of the present invention can detect Mycobacteri um tuberculosis, Mycobacteri um bovis BCG, Mycobacteri um african um, Mycobacteri um mi croti and Mycobacteri um canetti of Mycobacterium tuberculosis group
- the present invention relates to a probe, which comprises the nucleotide sequence of SEQ ID NO: 39 or a part thereof in the sequence listing, or the base sequence of SEQ ID NO: 11 in the sequence listing.
- a second invention of the present invention is a probe capable of detecting Neisseriago no rrhoeae of a phosphatium, which comprises the nucleotide sequence of SEQ ID NO: 27 or a part thereof.
- the present invention relates to a probe having the nucleotide sequence of SEQ ID NO: 21 in the sequence listing.
- a third invention of the present invention relates to a probe capable of detecting Chlamydia Ch1 amy.
- Diatracomatis comprising a base sequence represented by SEQ ID NO: 22 in the sequence listing.
- the fourth invention of the present invention relates to a probe capable of detecting HCV, wherein the probe has the nucleotide sequence of SEQ ID NOS: 34 or 35 in the sequence listing.
- the fifth invention of the present invention relates to a probe which can hybridize to a target nucleic acid of a pathogenic microorganism in an alkaline region.
- a probe capable of hybridizing to a target nucleic acid of a pathogenic microorganism in the pH region of pH 8 to 14 is suitable, and the target nucleic acid of the pathogenic microorganism is Mycobacterium tuberculosis, phosphorus bacterium, or Chlamydia. Probes that are any of the HCV-derived target nucleic acids are preferred.
- the target nucleic acid of the pathogenic microorganism is selected from the IS611 gene of the M.
- probes that can be hybridized can be suitably used.
- a probe consisting of the nucleotide sequence represented by No. 11 is exemplified.
- a probe consisting of the nucleotide sequence shown in SEQ ID NO: 27 of the sequence listing present in the cpp B gene of the bacterium or a nucleotide sequence containing a part thereof, preferably a nucleotide represented by SEQ ID NO: 21 in the sequence listing A probe consisting of a sequence is exemplified.
- a probe consisting of the nucleotide sequence shown in SEQ ID NO: 22 of the sequence listing present in chlamydia pLGV440, or a nucleotide sequence containing a part thereof, preferably represented by SEQ ID NO: 20 in the sequence listing A probe consisting of a base sequence is exemplified.
- the probes according to the first to fifth aspects of the present invention may be provided with a label.
- the probe is an oligonucleotide having a base sequence consisting of consecutive 8 to 53 bases among the base sequences represented by SEQ ID NOS: 11, 20, 21, 34 and 35 in the sequence listing. Therefore, when the probe is hybridized with the target nucleic acid, the fluorescence intensity is not suppressed. It may be a probe for detecting pathogenic microorganisms, which is characterized in that it has been obtained. Further, the probe may be a probe for detecting a pathogenic microorganism consisting of eight or more consecutive bases among the base sequences shown in SEQ ID NOS: 11, 20, 21, 34 and 35 in the sequence listing.
- the labeled fluorescent dye is a probe having a reporter fluorescent dye and a quencher dye, and among the base sequences shown in SEQ ID NOs: 11, 20, 21, 34, and 35 in the sequence listing, It may be a probe for detecting a pathogenic microorganism, which comprises at least 8 consecutive bases.
- the reporter dye is a fluorescein dye
- the quencher dye may be a DABCYL dye.
- a probe to which a label selected from a fluorescent substance, a dye, an enzyme, biotin, colloidal gold, and a radioisotope is added can be suitably used.
- a sixth invention of the present invention relates to a method for detecting a pathogenic microorganism, which comprises a step of using the probe of the first to fifth inventions of the present invention to perform hybridization with a target nucleic acid of the pathogenic microorganism.
- hybridization with a target nucleic acid of a pathogenic microorganism can be performed in an alkaline region.
- the pathogenic microorganism include tuberculosis bacillus, phosphorus bacterium, chlamydia, and HCV.
- the target nucleic acid is preferably the IS610 gene or a fragment thereof, and after amplifying the IS610 gene and / or a fragment thereof derived from Mycobacterium tuberculosis, the target nucleic acid is It is preferable to perform hybridization with the probe according to the first or fifth aspect of the present invention.
- the target nucleic acid is preferably the cpp B gene or a fragment thereof.
- the target nucleic acid and the fragment of the present invention are amplified.
- Hybridization is preferably performed with the probe of the second or fifth invention.
- the cppB gene and / or a fragment thereof derived from a phosphatium is amplified using a mer.
- the target nucleic acid is preferably pLGV440 or a fragment thereof.
- the amplified product and the fragment of the present invention are used. It is preferable to perform hybridization with the prop of the third or fifth invention.
- the chlamydia-derived pLGV440 and Z or their primers having the nucleotide sequences shown in SEQ ID NOs: 23 to 26 in the sequence listing, or primers having a sequence partially overlapping the sequences are used.
- the fragment is amplified.
- the target nucleic acid is preferably 5, untranslated region or fragment thereof of HCV, after amplifying the 5 5 untranslated region, and / or fragment thereof from HCV, amplified product and the present invention It is preferable to perform hybridization with the probe of the fourth or fifth invention.
- the seventh invention of the present invention includes a step of detecting a nucleic acid derived from a group of Mycobacterium tuberculosis, a bacterium, a bacterium, a chlamydia or an HCV using the method for detecting a target nucleic acid of a pathogenic microorganism of the sixth invention of the present invention.
- the present invention relates to a method for detecting a pathogenic microorganism.
- An eighth invention of the present invention is a method for detecting a pathogenic microorganism, comprising detecting an amplified nucleic acid obtained by a nucleic acid amplification method comprising the following steps.
- the primer is substantially complementary to the base sequence of the nucleic acid to be type III, contains at least one selected from deoxyribonucleotides or nucleotide analogs and ribonucleotides, and the liponucleotide is A chimeric oligonucleotide primer located at the 3 'end or 3' end of the primer;
- the base sequence of the nucleic acid which is It is preferred to use a reaction mixture containing a chimeric oligonucleotide primer having qualitatively homologous sequences.
- the chimeric oligonucleotide primer is a chimeric oligonucleotide primer represented by the following general formula can be suitably used.
- dN deoxyribonucleotide and Z or nucleotide analog
- N unmodified liponucleotide and / or modified ribonucleotide
- Part of dNa dN may be substituted with N
- c of the chimeric oligonucleotide primer may be 0, the nucleotide analog is a deoxyriboinosine nucleotide, a deoxyribouracil nucleotide, and the 'modified ribonucleotide is a -s) liponucleotide. You may.
- the method may include a step of detecting the increased ⁇ ⁇ nucleic acid using the probe of the first to fifth inventions of the present invention.
- the ninth invention of the present invention relates to a chimeric oligonucleotide primer for detecting a pathogenic microorganism represented by the following general formula.
- dN deoxyliponucleotide and Z or nucleotide analog
- N unmodified ribonucleotide and // or modified ribonucleotide Nucleotides, dN at some dNa sites may be substituted with N
- the nucleotide analog is a deoxyriboinosine nucleotide, a deoxylipoperacil nucleotide, and the modified ribonucleotide is ( ⁇ -S ) Chimeric oligonucleotide primers that are liponucleotides are preferred.
- chimeric oligonucleotide primers for detecting pathogenic microorganisms represented by SEQ ID NOs: 13 to 16, 23 to 26, and 28 to 31 in the sequence listing are preferable.
- a tenth invention of the present invention relates to a Mycobacterium tuberculosis-derived IS 611 having a base sequence shown in SEQ ID NO: 36 or 37 in the sequence listing or a sequence partially overlapping the sequence.
- the present invention relates to a primer for amplifying an HCV-derived 5, untranslated region and ⁇ Z or a fragment thereof, which have the nucleotide sequences shown in SEQ ID NOs: 41 to 43 in the column list or a sequence partially overlapping the sequence.
- the primer may be a chimeric oligonucleotide primer in which a part of the nucleotide sequence is substituted with a liponucleotide.
- a label may be added. Examples of the label include fluorescent substances, dyes, enzymes, biotin, and colloidal gold.
- the eleventh invention of the present invention relates to a composition for detecting a target nucleic acid, comprising the probe of the first to fifth inventions of the present invention.
- a twelfth invention of the present invention relates to a composition for detecting a target nucleic acid, comprising the primer of the ninth to tenth inventions of the present invention.
- the eleventh and twelfth inventions of the present invention can be used for detecting pathogenic microorganisms.
- a thirteenth invention of the present invention relates to a composition for use in the sixth to eighth pathogenic microorganism detection methods of the present invention, which comprises at least one of the following components for performing amplification or hybridization of a target nucleic acid.
- the present invention relates to a composition for detecting pathogenic microorganisms, comprising a species of reagent.
- the thirteenth invention of the present invention may comprise a reagent selected from a DNA polymerase having a strand displacement activity, RNase H, and deoxyribonucleotide triphosphate.
- the DNA polymerase may be a 5, ⁇ 3 ′ exonuclease-deficient B ca DNA polymerase derived from Bacillus caldotenax, and the RNaseH is derived from a bacterium belonging to the genus Pyrococcus and / or Ogropas (Ar chae og 1 obus).
- a fifteenth aspect of the present invention relates to a kit for detecting a pathogenic microorganism, which comprises the probe of the first to fifth aspects of the present invention.
- the fourteenth invention of the present invention may contain the ninth to tenth primers of the present invention.
- the kit can be used for the detection of M. tuberculosis, phosphorus, chlamydia, and HCV.
- the kit is a kit for use in the sixth to eighth pathogenic microorganism detection methods of the present invention, and includes at least one reagent for amplifying or hybridizing a target nucleic acid. You may. It may also contain a reagent selected from the group consisting of DNA polymerase having strand displacement activity, RNAse H, and deoxyribonucleotide triphosphate.
- the DNA polymerase is preferably a 5, ⁇ 3 'exonuclease-deficient Bca DNA polymerase derived from Bacillus cardotenax, and RNase H is derived from a bacterium belonging to the genus Pyrococcus and a bacterium derived from a bacterium belonging to the genus Pyrococcus or genus Zalca globus. Type II RNase H may be used. Further, a carrier for capturing the amplification product may be contained, and a carrier selected from microtiter plates, beads, magnetic beads, membranes, and glass can be suitably used.
- the fifteenth invention of the present invention relates to a method for detecting a group of Mycobacterium tuberculosis, comprising a step of treating a sample containing Mycobacterium tuberculosis with lamidase and extracting a nucleic acid.
- FIG. 1 is a diagram comparing the relationship between the HCV-RNA concentration and the change in fluorescence intensity when various HCV-RNA concentrations are measured by the method of the present invention, and the difference in the measurement range from the conventional method. Detailed description of the invention
- deoxyribonucleotide refers to a nucleotide in which the sugar moiety is composed of D-2-deoxylipose. Also has adenine, cytosine, guanine, and thymine Is included.
- deoxyliponucleotide analogs such as deoxyliponucleotides and deoxyinosine nucleotides having modified bases such as 7-deazaguanosine are also included in the above deoxyribonucleotides. '
- liponucleotide refers to a nucleotide in which the sugar moiety is composed of D-ribose, and has adenine, cytosine, guanine, and peracil in the base moiety. Is mentioned. Furthermore, the liponucleotide includes a modified liponucleotide, for example, a modified ribonucleotide in which an oxygen atom of a phosphate group at the ⁇ -position is replaced with a sulfur atom [(a-S) liponucleotide; And other derivatives.
- a chimeric oligonucleotide primer refers to a primer containing a deoxyliponucleotide and a liponucleotide.
- the primer may contain nucleotide analogs and / or modified nucleotides.
- a liponucleotide is arranged at the 3, terminal or 3, terminal side of the primer, the nucleic acid chain can be extended in the method of the present invention, can be cleaved with end nuclease, and the strand can be displaced. Any one that can perform the reaction is included in the chimeric oligonucleotide primer of the present invention.
- the term “3 ′ end” refers to a nucleic acid, for example, a portion of a primer from the center to the 3 ′ end.
- the terminus 5 refers to a portion of a nucleic acid from its center to the 5 'end.
- the endonuclease is defined as a ribonucleotide portion of the primer which acts on a double-stranded ⁇ ⁇ , ⁇ generated by extending DNA from the chimeric oligonucleotide primer annealed to the ⁇ -type nucleic acid, and It is only necessary that the DNA be specifically cleaved.
- a DNA polymerase refers to an enzyme that synthesizes a new DN ⁇ chain using a DNA chain as a ⁇ type.
- a mutant enzyme having the above activity is also included. Included.
- the enzyme include DNA polymerase having a strand displacement activity, 5 ′ ⁇ 3 ′ exonuclease.
- the DNA polymerase include a DNA polymerase having no enzyme activity 1 "and a DNA polymerase having a reverse transcriptase activity and a nuclease activity.
- strand displacement activity means that when performing DNA replication in accordance with a nucleic acid sequence of type ⁇ , the DNA strand proceeds while displacing the DNA strand and releases a complementary strand that has been annealed to the type ⁇ strand. An activity that can be displaced. Further, in the present specification, a DNA strand released from a nucleic acid sequence having a ⁇ shape due to strand displacement is referred to as a “substituted strand”.
- aliphatic region refers to a region where the pH exceeds 7.
- pathogenic microorganisms refer to pathogenic bacteria and viruses.
- target nucleic acid refers to any region of a gene derived from a pathogenic microorganism to be amplified or detected, and includes both DNA and RNA.
- the probe of the present invention is characterized by being capable of detecting a pathogenic microorganism, for example, a tubercle bacillus group, a bacterium, a chlamydia or HCV.
- a preferred embodiment of the probe of the present invention is exemplified by a probe capable of stably hybridizing to a target nucleic acid in the target region. That is, the probe capable of hybridizing in the alkaline region of the present invention is not particularly limited, but for example, an alkaline region having a pH exceeding 7.0, preferably having a pH in the range of 8 to 14, and particularly preferably having an pH in the range of pH 8 to pH 10.
- Probes capable of hybridizing with a target nucleic acid having a sequence complementary to the base sequence under the conditions of force may be mentioned.
- the probe of the present invention can be used for conventional hybridization in a neutral region.
- double-stranded nucleic acid can be denatured to single-stranded by an aliquot treatment and then used in the hybridization step without neutralization. is there. This simplifies the process and improves sensitivity by more than 10 times compared to the conventional method. Up. In addition, by performing hybridization in an alkaline region, the specificity of hybridization can be improved.
- the method for detecting a probe hybridized with a nucleic acid derived from a specimen is not particularly limited, and any known detection method can be applied to the present invention.
- a target nucleic acid present in a sample can be detected efficiently and Z or with high sensitivity.
- the method of labeling the probe is not limited, and for example, radioisotopes (eg, 32 P), dyes, fluorescent substances, luminescent substances, various ligands (eg, biotin, digoxigenin), enzymes and the like can be used.
- the presence of the labeled probe can be confirmed by a detection method according to the label.
- a ligand that cannot be directly detected it may be combined with a ligand-binding substance with a detectable label.
- a target nucleic acid can be detected with high sensitivity by combining a ligand-labeled probe with an enzyme-labeled anti-ligand antibody and amplifying the signal.
- the probe may have a labeling substance for detection.
- the labeling substance is not particularly limited, and for example, any of a ligand or receptor substance, a radioisotope, fluorescence, luminescence, and coloring can be suitably used.
- a method of hybridizing a probe having a labeling substance with a nucleic acid having an amplified target region and detecting a free probe after washing, or eliminating the washing step is omitted.
- the deviation of the so-called homogenous air detection method can also be suitably used.
- the homogenous detection method using fluorescence for example, Proc.
- the 5 ′ end of the probe is labeled with a damine or oxazine dye
- the 3 ′ end is a base sequence that causes quenching.
- Examples are the molecular beacon method and the smart probe method, in which the probe is labeled with a lignonucleotide-reporter dye, and furthermore, the 5, 5 and 3, terminal sides of the probe are senorefreferred.
- the probe hybridizes to the amplified nucleic acid, thereby eliminating the sefani ring structure of the probe and consequently reducing the fluorescence intensity. It emits a fluorescent signal without being suppressed.
- the probe retains the self-annealing structure and the fluorescence intensity is suppressed, so that no fluorescent signal is detected.
- the fluorescent dye is preferably a rhodamine dye or an oxazine dye, and the dye is bound to the 5 'end of the probe and cooperates with the base sequence at the 3' end to bind to the target nucleic acid. If the fluorescent probe is not bound, the fluorescence intensity is suppressed, and if the fluorescent probe is bound to the target nucleic acid, the fluorescence intensity is not suppressed.
- the fluorescence intensity is suppressed by fluorescence resonance energy transfer, and when bound, the combination is such that the fluorescence intensity is not suppressed. I just need to be.
- fluorescent dyes include FAM (6-carboxy-fluorescein), ⁇ AMRA (6-carboxytetramethyl-rhodamine), JA242 (oxazine), and DABCYL (4-dimethylaminoazobenzene-1'4'-1). Sulphoyuric ride) is preferred. These fluorescent dyes are known and are commercially available.
- the chain length of the probe of the present invention is not particularly limited, but is, for example, 12 mer or more, preferably 2 Omer or more, particularly preferably 4 Omer or more.
- the probe for detecting Mycobacterium tuberculosis of the present invention is My cobacteiut uber. culosis, Mycobacterium um bovis BCG, Mycobacterium africanum, Mycobacterium um microti and Z or Mycobacterium um canetti can be detected.
- the target nucleic acid may be selected appropriately depending on the target nucleic acid to be detected or the organism, and is not particularly limited.For example, in the detection of a tuberculosis group, the target is the IS6110 gene.
- a probe as a nucleic acid can be used.
- the nucleotide sequence of the tubercle bacillus-derived IS6110 gene shown in SEQ ID NO: 12 in the sequence listing can be designed by selecting an appropriate region.
- a region containing the nucleotide sequence of SEQ ID NO: 39 in the sequence listing preferably a region containing SEQ ID NO: 40 in the sequence listing, and more preferably a sequence containing SEQ ID NO: 38 in the sequence listing You can select from the area. In particular, it can be selected from a region containing the nucleotide sequence of SEQ ID NO: 11 in the sequence listing.
- the above-mentioned probe is particularly useful for detection of the tubercle bacillus group because it stably hybridizes with the IS 6110 gene derived from the tubercle bacillus group or a fragment thereof with high specificity. .
- the probe for detecting a bacterium according to the present invention can detect Neisse riag ogno rr hoe ae.
- the probe may be selected as the target nucleic acid according to the nucleic acid to be detected or an organism, and is not particularly limited.
- cryptic 1 asmidproteinB cp pB
- a probe that uses a gene as a target nucleic acid can be used, and can be designed by selecting an appropriate region from the nucleotide sequence of the cpp B gene derived from a bacterium shown in SEQ ID NO: 27 in the sequence listing.
- the above-mentioned probe hybridizes stably and with high specificity with the cppB gene derived from a bacterium or a fragment thereof, it is particularly useful for detection of the gene and further detection of a bacterium.
- the chlamydia detection probe of the present invention can detect Chlamydia diatrach omatis.
- the probe attempts to detect the target nucleic acid It is sufficient to select an appropriate nucleic acid or an appropriate one according to the organism, and there is no particular limitation.For example, in the detection of chlamydia, a cryptic plasmid
- a probe targeting pLGV440 as a target nucleic acid can be used, and can be designed by selecting an appropriate region from the base sequence of chlamydia-derived pLGV440 shown in SEQ ID NO: 22 in the sequence listing.
- SEQ ID NO: 22 the base sequence of chlamydia-derived pLGV440 shown in SEQ ID NO: 22 in the sequence listing.
- a region containing the nucleotide sequence of SEQ ID NO: 22 in the sequence listing preferably from a region containing SEQ ID NO: 44 in the sequence listing, more preferably from a region containing SEQ ID NO: 20 in the sequence listing .You can choose.
- the above-mentioned probe hybridizes stably and with high specific 1 "life with chlamydia-derived pLGV440 or a fragment thereof, and is therefore particularly useful for detection of the gene and further detection of chlamydia.
- the HCV detection probe of the present invention is not particularly limited as long as it is a probe that can hybridize to the nucleotide sequence of the region between the forward primer and the reverse primer used for amplification of the target nucleic acid.
- the length of the probe is not particularly limited, but is preferably in the range of 8 to 53 bases, and particularly preferably in the range of 8 to 36 bases.
- a probe having a base sequence of 8 or more bases continuous in the above range may be selected from the base sequence shown in SEQ ID NO: 43 of the sequence listing, and is not particularly limited. Probe having 8 or more consecutive bases in the base sequence to be used.
- a neutralization step following a denaturation step of a target nucleic acid from a double strand to a single strand can be omitted by using the probe described in the above (1). That is, in the method for detecting a target nucleic acid of the present invention, the nucleic acid has a sequence complementary to its base sequence under pH conditions of more than 7, particularly preferably pH 8 to 14. It is possible to hybridize with nucleic acids.
- the conditions for the hybridization are not particularly limited, and include those known to those skilled in the art as “strict conditions”. These conditions were published in 1989 by Cold 'Spring Harbor Laboratory, edited by T. Maniatis et al., Molecular. Clawing: A' Laboratory '. The ones listed in IB in Mayuanole 2nd edition (Molecular Cloning: A Laboratory Manual 2nd ed.) And those described in Examples of the present application can be used.
- the typical composition of the hybridization solution is as follows: 0.5% SDS, 5X Denhardt's; 0.1% ⁇ serum albumin (BSA), 0.1% polyvinylpyrroli Don, 0.1% Ficoll 400] and
- the pH of the hybridization solution may be adjusted in the range of 8 to 14.
- the temperature of the hybridization is not particularly limited. For example, the hybridization is performed at a temperature lower than the Tm value of the probe by 5 ° C. or more.
- the Tm value of the probe is, for example, the following equation:
- Tm 81. 5—16.6 (lo gl . [Na +]) +0.41 (% G + C) one (600 / N)
- Tm (% A + T) X2 + (% G + C) X4]
- (% A + T) is the content of adeyun and thymine residues in the probe
- (% G + C) is the content of guanine and cytosine residues in the probe.
- Hybridization conditions in the detection method of the present invention are not particularly limited, and known hybridization conditions, preferably strict hybridization conditions, are used. Further, the pH of the hybridization solution may be adjusted in the range of 8 to 14.
- a probe suitable for detecting the IS611 gene derived from a tubercle bacillus group can be suitably used, and although not limited, for example, as described in SEQ ID NO: 39 in the sequence listing
- the base sequence or a part thereof, preferably the base sequence or a part thereof described in SEQ ID NO: 40 of the sequence listing, more preferably the base sequence of SEQ ID NO: 38 or a part thereof, particularly preferably A probe containing SEQ ID NO: 11 in the sequence listing can be suitably used in the present invention.
- a probe suitable for detecting the cppB gene derived from a bacterium can be suitably used, and is not particularly limited.
- a nucleotide sequence or a part thereof, preferably a probe containing the nucleotide sequence of SEQ ID NO: 21 or a part thereof in the Sequence Listing can be suitably used in the present invention.
- a probe derived from chlamydia; suitable for detecting PL GV440 can be suitably used, and is not particularly limited.
- a 5 ′ untranslated region is preferable, for example, the base sequence described in SEQ ID NO: 43 in the sequence listing or a part thereof, preferably A probe containing the nucleotide sequence of SEQ ID NO: 34 or a part thereof, or the nucleotide sequence of SEQ ID NO: 35 or a part thereof can be suitably used in the present invention.
- the method for detecting a pathogenic microorganism of the present invention can specifically detect each pathogenic microorganism by using the probe described in (1) above. That is, the above-mentioned probe hybridizes stably with a gene or a fragment thereof derived from each pathogenic microorganism and has a high specific indigenous organism, so that the detection of the gene and the detection of each pathogenic microorganism can be performed. Especially useful for:
- the use of the probe according to the above (1) allows the probe and the sample containing a nucleic acid to have a pH of more than pH 7, preferably under pH conditions.
- Hybridization can be carried out under the conditions of 8 to 14, particularly preferably pH 8 to 10. That is, the method provides a method for detecting a gene or a fragment thereof derived from a pathogenic microorganism without passing through a neutralization step following a denaturation step of a target nucleic acid. Etc. can be detected.
- the method of the present invention can be used for detection and quantification of a specific gene present in a sample. That is, a specific gene can be detected and quantified from any sample that may contain a nucleic acid such as DNA or RNA.
- RNA or DNA is suitably used as the nucleic acid used as type I for the above detection method.
- the preparation of a preparation having a nucleus from these materials is not particularly limited, and can be performed by, for example, dissolution treatment with a surfactant, ultrasonic treatment, shaking and stirring using glass beads, use of French press, and the like. .
- it may be advantageous to purify the nucleic acid with further manipulations eg, when endogenous nucleases are present.
- the nucleic acid is purified by known methods such as phenol extraction, chromatography, ion exchange, gel electrophoresis or density gradient centrifugation.
- the method of the present invention may be carried out using cDNA as a type II cDNA synthesized by a reverse transcription reaction using the type RNA as a type II.
- the primer used in the above reverse transcription reaction is not particularly limited as long as it anneals to type I RNA under the reaction conditions used.
- the primer includes a primer having a base sequence complementary to a specific type I RNA (specific primer), an oligo dT (deoxythymine) primer and a primer having a random sequence (random primer) It may be.
- the length of the reverse transcription primer is preferable from the viewpoint of performing specific annealing. Yes, more preferably 9 nucleotides or more, and from the viewpoint of oligonucleotide synthesis, preferably 100 nucleotides or less, more preferably 30 nucleotides or less.
- a chimeric oligonucleotide primer that can be used as a primer for a strand displacement reaction when performing the nucleic acid amplification method of the present invention using the reversely transcribed cDNA as a ⁇ type can be used.
- Such primers are not particularly limited as long as they have the properties described in the following (3) and can be used for the reverse transcription reaction from RNA, for example, SEQ ID NO: 32 and SEQ ID NO: 32 in the sequence listing.
- a primer having the base sequence described in 33 can be suitably used.
- the enzyme used in the above reverse transcription reaction is not particularly limited as long as it has an activity of synthesizing cDNA with RNA type II.
- reverse transcriptase derived from avian myeloblastosis virus AMV RTa se
- reverse transcriptase derived from Moro-mouse murine leukemia virus MMLV RTase
- Rousse-related virus 2 reverse transcriptase Rousse-related virus 2 reverse transcriptase
- an enzyme having a reverse transcription activity at a high temperature is suitable, for example, a DNA polymerase derived from a bacterium belonging to the genus Thermus sp.
- Tth DNA polymerase or the like a DNA polymerase derived from a bacterium belonging to the thermophilic bacillus genus, or the like. Can be used. Although not particularly limited, for example, DNA polymerase derived from a thermophilic Bacillus bacterium is preferred, DNA polymerase derived from B.st (Bst DNA polymerase), and Bea DNA polymerase is more preferred.
- Bst DNA polymerase DNA polymerase derived from B.st (Bst DNA polymerase)
- Bea DNA polymerase does not require manganese ions for the reverse transcription reaction, and can synthesize cDNA while suppressing the formation of secondary structure of type I RNA under high temperature conditions.
- the enzyme having the above reverse transcriptase activity both natural and mutant enzymes can be used as long as the enzyme has the activity.
- double-stranded DNA such as genomic DNA and PCR fragments isolated by the above method
- single-stranded DNA such as cDNA prepared by reverse transcription from total RNA or mRNA
- It can be suitably used as type ⁇ DNA in the nucleic acid ⁇ method.
- a DNA that has been subjected to a step of denaturing single-stranded DNA (denaturing) can be suitably used.
- the nucleic acid can be amplified by a simple nucleic acid amplification method and used for hybridization.
- the nucleic acid amplification method used is not particularly limited as long as it can amplify a region on the target nucleic acid.
- PCR polymerase chain reaction
- the ICAN method is a method for continuously amplifying DNA having a specific base sequence on type I nucleic acid under isothermal conditions using a chimeric nucleotide primer, an endonuclease, and a DNA polymerase having strand displacement activity.
- “continuously” means that the reaction is proceeding without changing the reaction temperature and the composition of the reaction solution.
- “isothermal” means a substantially constant temperature condition under which an enzyme and a nucleic acid chain function in each of the above steps.
- a chimeric oligonucleotide primer composed of a deoxyribonucleotide and a ribonucleotide and having a ribonucleotide arranged at the 3 ′ end or 3 ′ end thereof is used.
- an oligonucleotide having a structure represented by the following general formula can be used as a primer in the ICAN method. "General formula: 5, -dNa-Nb-dNc-3 '
- nucleotide analogs include, for example, deoxylipoinosine
- nucleotide and the modified liponucleotide for example, ( ⁇ -S) ribonucleotide can be used, respectively.
- the nucleotide analog can be contained within a range that does not substantially lose the function as a primer.
- the primer has a sequence homologous to the base sequence on the 5 'side and a base sequence on the 3' side based on the base sequences on the 5, 5 and 3 sides of the region where amplification on type III is desired. Two complementary species are created and used for amplification.
- the endonuclease used in the present invention is a strand displacement reaction that acts on a double-stranded DNA generated by extending DN DN from the above-described chimeric oligonucleotide primer that has been annealed to type III nucleic acid, and What is necessary is just to be able to cleave the extended strand so that the above-mentioned occurs. That is, it is an enzyme capable of generating a nick in the chimeric oligonucleotide primer portion of the double-stranded DNA.
- ribonuclease can be used in the present invention, and in particular, endoliponuclease H (RNase H) which acts on the RNA portion of a double-stranded nucleic acid formed from DNA and RNA is preferable.
- RNase H endoliponuclease H
- any of the liponucleases having a normal temperature to a thermostability can be suitably used in the present invention as long as they have the above-mentioned action.
- RNase H derived from Escherichia coli (E.co1i) can be used in the method of the present invention in a reaction at about 50 ° C. to about 70 ° C.
- thermostable liponuclease in the method of the present invention, can also be suitably used.
- the thermostable ribonuclease is not particularly limited, but, for example, commercially available Hybridase TM Thermo stable RNase
- RNaseH derived from thermophilic Bacillus, Sirmas, Pyrococcus, Thermotoga, Alcaeoglobus, Methanococcus, etc. It can be suitably used. Furthermore, as the liponuclease, any of a natural form and a mutant can be suitably used.
- the enzyme unit of RNaseH described in the specification of the present application is a numerical value displayed based on the enzyme unit measuring method shown in the reference example in the examples.
- the RNaseH is not particularly limited as long as it can be used in the method of the present invention, and may be any of various viruses, phages, prokaryotes, and eukaryotes.
- cellular RNase H or viral RNase H It may be a deviation.
- the above-mentioned cellular RNaseH is Escherichia coli RNaseHI and the viral RNaseH is, for example, HIV-1 derived RNaseH.
- any of type I, type II, and type III RNaseH can be used.
- RNase HI derived from Escherichia coli RNase HI derived from a bacterium belonging to the genus Pyrococcus or bacterium belonging to the genus Alcaeoglobus
- the efficiency of the cleavage reaction of the endonuclease used in the method of the present invention depends on the base sequence near the 3 'end of the primer, and may affect the amplification efficiency of the desired DNA. Therefore, it is natural to design the optimal brammer for the RNase H to be used.
- a DNA polymerase having an activity of performing strand displacement of DNA is used. Those having substantially no 5, ⁇ 3, exonuclease activity are particularly preferably used.
- the DNA polymerase used in the ICAN method is not particularly limited as long as it has the above strand displacement activity.
- Bacillus caldotenax hereinafter referred to as B.ca
- thermophilic Bacillus bacteria-derived DNA polymerases that lack the 5, ⁇ 3 'exonuclease activity or large fragments of Escherichia coli-derived DNA polymerase I (Tarenow cleavage) Fragment) and the like.
- the DNA polymerase any one of from room temperature to heat can be suitably used.
- the above enzyme may be any of those obtained by purifying from its original source, or recombinant proteins produced by genetic engineering.
- the enzyme may be modified by substitution, deletion, addition, insertion or the like by genetic engineering or other techniques.
- Examples of such an enzyme include 5 ′ ⁇ 3, B ca BEST DNA polymerase (manufactured by Takara Shuzo), which is a B ca DNA polymerase lacking exonuclease activity, and the like.
- the enzyme shows activity at 50 ° to 70 ° and can be suitably used in the method.
- DNA polymerases under certain conditions have an endonuclease activity, For example, those having RNaseH activity are known.
- Such DNA polymerase can be used in the method of the present invention. That is, there is an embodiment in which the DNA polymerase is used under conditions such that RNase H activity is expressed, for example, in the presence of Mn 2 + .
- it is possible to implement the Ku method of the present invention such addition of the RNa S eH. That is, in a buffer containing Mnz + , the above-mentioned Bca DNA polymerase can exhibit RNase H activity.
- the above embodiment is not limited to Bca DNA polymerase, and Known DNA polymerases known to have the same, such as Tth DNA polymerase derived from Thermus therraophilus, can also be used in the present invention.
- a chimeric oligonucleotide primer In the ICAN method, a chimeric oligonucleotide primer, a sample containing a nucleic acid to be type III, an endonuclease, a DNA polymerase, a deoxyribonucleotide triphosphate (dNTP), etc. This is carried out by mixing in a buffer solution and keeping the reaction solution at an appropriate temperature for a period of time sufficient to generate a reaction product.
- dNTP deoxyribonucleotide triphosphate
- the chimeric oligonucleotide primer and the nucleic acid to be type III are mixed and maintained at a temperature at which the double-stranded nucleic acid is denatured, for example, at 90 ° C or higher, and then the reaction used in the method of the present invention is performed.
- the annealing may be performed by cooling to below the temperature. This is not an essential operation for the amplification reaction.
- RNA when RNA is type II, the reverse transcription reaction and the nucleic acid amplification reaction may be performed in one step.
- examples of a combination of a reverse transcriptase and a strand-replaceable DNA polymerase include AMV RTase, MMLVRTase, or RAV-21, 36 and 8. & A combination of DNA polymerases can be suitably used. Further, one kind of DNA polymerase having reverse transcriptase activity and strand displacement activity may be used.
- the method for detecting a target nucleic acid of the present invention can be carried out by directly detecting the target nucleic acid from a sample containing the nucleic acid.
- the chain length of the target nucleic acid to be expanded is not particularly limited, but from the viewpoint of detecting the target nucleic acid with high sensitivity, for example, a region of 200 bp or less, more preferably 150 bp or less is effective.
- the width of the chain By setting the chimeric oligonucleotide primer of the present invention such that the target nucleic acid in the sample can be detected with high sensitivity.
- a reaction buffer containing a bicine, tricine, a mouse, a phosphate, or a tris buffer component, and an annealing solution containing a spunolemidine or propylene diamine are used.
- the target nucleic acid can be detected with even higher sensitivity from a small amount of nucleic acid sample.
- the endonuclease and the DNA polymerase to be used are not particularly limited. For example, a combination of Escherichia coli, Pyrococcus bacteria or Alkaeoglobus bacteria RNaSeH and BcaBESTDNA polymerase is preferable.
- the number of units that can be suitably used for the above-mentioned endonucleases and DNA polymerases may differ depending on their types.
- improvement of the detection sensitivity or increase in the amount of the amplified product is used as an index.
- the composition of the buffer and the amount of enzyme added may be adjusted.
- each ⁇ DNA during the extension reaction from each primer is used.
- Type II exchange may occur between the intermediates of the extended strands, and the synthesized primer extended strands may produce a double-stranded nucleic acid in which the two have been annealed.
- This double-stranded nucleic acid has chimeric oligonucleotide primers at both ends, and then a complementary strand elongation reaction by strand displacement can be started again from both ends.
- an amplification product having a primer sequence at one end is generated.
- type ⁇ exchange occurs during this reaction, the same double-stranded nucleic acid as described above is generated again.
- a nucleic acid amplification method including a step of performing a type I exchange reaction using a DNA polymerase having the above strand displacement activity
- the DNA polymerase having the ability to carry out the type I exchange reaction during the strand displacement reaction include, for example, a mutant enzyme of Bca DNA polymerase lacking 5 ′ ⁇ 3 ′ exonuclease activity. It is preferably used.
- This enzyme is commercially available as Bca BESTDNA polymerase (manufactured by Takara Shuzo), and Escherichia coli HB101 / pUI205 (FERM BP-3720, Tsukuba East 1-chome, Ibaraki Pref. 1 Chuo No. 6 (Zip code 3 05-8566) May 10, 1991 at the Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology B) can be prepared by the method described in Japanese Patent No. 2978001.
- dUTP can be incorporated as a substrate during amplification of a target nucleic acid. Therefore, when dUTP is used as a substrate, the amplification product is degraded using ⁇ lacinole N-glycoside, and urase 1 N-glycosidase (U NG). This can prevent false positives caused by the situation.
- a known nucleic acid detection method for example, a method of detecting a reaction product of a specific size by electrophoresis, or a hybridization with a probe Detection by zession or the like can be used. Further, a detection method using a combination of magnetic beads and the like can also be suitably used.
- a fluorescent substance such as ethidium bromide is usually used, but hybridization with a probe may be used in combination.
- the probe may be labeled with a non-radioactive substance such as biotin or a fluorescent substance in addition to labeling with a radioisotope.
- a labeled nucleotide in the above-mentioned step (b), it is possible to incorporate a labeled nucleotide into an amplification product to facilitate detection.
- detection using a fluorescence polarization method, fluorescence energy transfer, or the like can be performed.
- an appropriate detection system it is possible to automatically detect the target nucleic acid or to quantify the target nucleic acid. Also, a naked eye detection method using a hybrid chromatography method can be suitably used.
- RNA probes or chimeric oligonucleotide probes composed of liponucleotides and deoxyribonucleotides, labeled with two or more fluorescent substances, arranged at a distance so as to be in the quenching state, were used in the present invention.
- the probe does not fluoresce.
- RNaseH degrades the probe when applied to amplified DNA from the target nucleic acid that is complementary to it. As a result, the distance between the fluorescent substances on the probe is reduced. A lot of fluorescence is emitted, and the presence of the target nucleic acid can be known.
- a target nucleic acid can be detected only by adding the above probe to the reaction solution.
- a fluorescent substance used for labeling the probe for example, a combination of 6-FAM (6-carboxyfluorescein) and TAMRA (N, N, N ,, N, -tetramethyl-6-carboxyrhodamine) is preferable.
- 6-FAM 6-carboxyfluorescein
- TAMRA N, N, N ,, N, -tetramethyl-6-carboxyrhodamine
- the width method under isothermal conditions is used in the detection method of the present invention
- a device such as a thermal cycler is not required.
- the number of primers to be used can be one or two, which is smaller than that of the conventional method. Since a reagent such as dNTP used in PCR or the like can be used, the running cost can be reduced as compared with the conventional method. Therefore, it can be suitably used in fields such as genetic testing where routine work is performed. Furthermore, since the method of the present invention can obtain more amplification products in a shorter time than the PCR method, it can be used as a simple, rapid, and highly sensitive gene detection method.
- a means for analyzing a large amount of a sample may be combined with a means for slightly reducing the reaction system and further increasing the degree of integration.
- One of the means is to use the most advanced ultrafine processing technology to apply the basic process of the detection method of the present invention, for example, the process of extracting DNA from cells, nucleic acid amplification reaction, detection of target DNA, etc. May be combined on a microchip having a size of several cm square to a fingertip.
- gel or capillary electrophoresis, and a hybridization process with a detection probe may be combined.
- the system is also referred to as a microphone or chip, and it is also referred to as a chip or a nanochip.
- any nucleic acid amplification reaction can be used as long as the target DNA fragment is amplified.
- a method capable of amplifying a nucleic acid under isothermal conditions such as the ICAN method, can be suitably used.
- the system can be simplified, and it is very suitable for use in an integrated system as described above.
- a chimeric oligonucleotide primer for detecting a Mycobacterium tuberculosis group having a base sequence represented by each of SEQ ID NOS: 13 to 16 in the Sequence Listing, SEQ ID NOS: 28 to 29 in the Sequence Listing A chimeric oligonucleotide primer for detecting a bacterium having a nucleotide sequence represented by SEQ ID NO: 23, a chimeric oligonucleotide primer for detecting chlamydia having a nucleotide sequence represented by each of SEQ ID NOS: 23 to 26 in the sequence listing, SEQ ID NO: in the sequence listing
- a chimeric oligonucleotide primer for detecting HCV having a nucleic acid sequence represented by each of 30 to 31 can be suitably used.
- the target nucleic acid in the sample is amplified using the chimeric oligonucleotide primer, and the target a
- a probe for detecting a Mycobacterium tuberculosis group selected from the regions containing the nucleotide sequences represented by SEQ ID NOS: 11, 12, and 38 to 40 in the sequence listing, and the sequence in the sequence listing A probe for detecting a bacterium selected from the region containing the nucleotide sequence represented by No. 27; a probe for detecting a chlamydia selected from the region containing the nucleotide sequence represented by SEQ ID NOS: 22 and 44 in the sequence listing;
- the target nucleic acid can be detected using an HCV detection probe selected from the regions containing the nucleotide sequences represented by SEQ ID NOs: 43 to 45 in the sequence listing.
- a required reaction apparatus may be a thermostatic layer, and a strict apparatus such as a thermal cycler is not required.
- a device for measuring the label signal a commercially available spectrophotometer, fluorescence detector, plate reader, or the like can be used. Therefore, large-volume rapid sample measurement is possible in the place where normal inspection work is performed. Further, reagents necessary for the method of the present invention are also on the market.
- RNA of HCV extracted from a sample by a conventional method
- a primer for a reverse transcription reaction a reverse transcriptase (a DNA polymerase having a reverse transcription activity is used. If you do not need reverse transcriptase), dATP, dGTP, dCTP, 11: Ding?
- a mixed nucleic acid solution is prepared, and the target nucleic acid is amplified with the chimeric oligonucleotide primer and the DNA polymerase for ICAN using the cDNA generated from HCV-RNA at a constant temperature as type III, On this Hybridize with the fluorescent labeled probe in a homogenous system and measure the fluorescence intensity. Specific conditions for the reaction are described in detail in the Examples below.
- cDNA is synthesized using HCV-RNA as type II, and then DNA is amplified by ICAN method using this cDNA as type II. Since the amplified DNA contains a region complementary to the fluorescent probe, the fluorescent probe hybridizes to the single-stranded amplified DNA. When the fluorescent probe hybridizes, the suppression of the fluorescence intensity is released and the fluorescence intensity increases. On the other hand, when HCV RNA does not exist in the sample, hybridization does not occur, and the fluorescence intensity is suppressed and the fluorescence intensity is weak. Therefore, by measuring the fluorescence intensity, the RNA of HCV in the sample can be detected simply, quickly and with high sensitivity.
- HCV RNA is measured as a fluorescence intensity without a washing step in a homogenous system.
- the present invention is also advantageous in that simultaneous measurement of multiple items can be performed by changing the measurement wavelength by changing the fluorescent dye. That is, at blood centers, not only HCV but also HBV, HIV, and HTLV are important test items.Specific ICAN primers and probes are prepared for each, and each probe is labeled with a fluorescent dye having a different measurement wavelength. By doing so, it is possible to measure the above items simultaneously.
- a chimeric oligonucleotide primer is exemplified.
- the primer is composed of a deoxyliponucleotide, a nucleotide analog, an unmodified or modified liponucleotide, and has a liponucleotide arranged at the 3, terminal or 3 'terminal thereof.
- an oligonucleotide having a structure represented by the following general formula can be used as a primer in the ICAN method.
- dN Deoxyliponucleotide and / or nucleotide analog
- N Unmodified ribonucleotide and Z or modified liponucleotide nucleotides, Note, d N a part of d N sites may be substituted by N
- nucleotide analogs include, for example, deoxyriboinosine nucleotides, deoxyribouracil nucleotides or modified deoxyribonucleotides, and the modified liponucleotides include, for example, (HIS) ribonucleotides. , Can be used respectively.
- the primer has a sequence homologous to the 5'-side and 3'-side nucleotide sequences based on the 5'-side and 3'-side nucleotide sequences of the region of type III where amplification is desired, and has a 3'-side nucleotide sequence. Two complementary species are created and used for amplification.
- nucleic acid amplification reaction for example, after performing a nucleic acid amplification reaction by the above-described method on a sample from which a group of M. tuberculosis is to be detected, hybridization is performed between the amplified product and the probe of the present invention.
- a group of Mycobacterium tuberculosis can be detected.
- Primers for nucleic acid amplification were designed for use in various nucleic acid amplification methods with reference to the nucleotide sequence of the Mycobacterium tuberculosis complex IS 6110 gene shown in SEQ ID NO: 12 in the sequence listing. , Can be produced.
- a region containing the base sequence shown in SEQ ID NO: 39 of the sequence listing in the IS610 gene or a region containing a part thereof preferably the base sequence shown in SEQ ID NO: 40 in the sequence listing or A region capable of amplifying a region containing a part thereof, more preferably a region containing the base sequence shown in SEQ ID NO: 38 in the sequence listing or a part thereof is suitable for the present invention.
- SEQ ID NO: 11 It is useful for amplification of a gene or a fragment thereof.
- the detection can be suitably performed by using a probe for detecting phosphorus bacterium, chlamydia, HCV, and a chimeric oligonucleotide primer.
- the primer is not limited to the above-mentioned base sequence, and those having a sequence around the base sequence, that is, a sequence partially overlapping the sequence, can be suitably used in the present invention. That is, a primer can be prepared by selecting an appropriate nucleotide sequence overlapping with the sequence according to the characteristics of the nucleic acid amplification method to be used.
- chimeric oligonucleotide primers are designed to have an arbitrary nucleic acid sequence, for example, Applied Biosystems (ABI, Applied Biosystems).
- the deoxyliponucleotide at the 3 ′ terminal of the primer may be replaced with liponucleotide so that it can be used in the method.
- An example of such a primer is a chimeric oligonucleotide primer having a base sequence represented by each of SEQ ID NOS: 13 to 16, 23 to 26, and 28 to 31 in the sequence listing.
- these primers may be labeled with an appropriate substance, for example, a fluorescent substance, a dye, a ligand (eg, biotin, digoxigen), or colloidal gold.
- an appropriate substance for example, a fluorescent substance, a dye, a ligand (eg, biotin, digoxigen), or colloidal gold.
- a primer labeled with a ligand for example, use a primer labeled with a ligand.
- a highly sensitive and simple quantitative measurement method is provided, such as capturing the amplified target nucleic acid on a carrier.
- the solid phase include microtiter plates, beads, magnetic beads, membranes, and glass.
- Extracted DNA samples from sputum specimens contain not only human DNA but also DNA derived from bacteria resident in the respiratory tract and viruses. Therefore, in order to investigate the specificity of the primer developed in the present invention, an attempt was made to amplify the M. tuberculosis group gene using sputum from Porantia, which had no history of M. tuberculosis infection. The lack of a positive result in such a test may prove the specificity of this primer.
- the present invention provides a composition used for the detection method of the present invention (2).
- the yarn composition include those containing the probe described in the above (1) and the primer described in the above (3).
- it may be in the form of a detection composition containing the above-mentioned probe and an amplification composition containing the above-mentioned primer.
- it may be in the form of a composition containing magnesium acetate and a composition containing a primer.
- it may contain a buffer component, dNTP and the like.
- it may contain a modified deoxyribonucleotide or an analog of deoxynucleotide triphosphate.
- composition of the present invention may contain an internal standard (I C; int ern alc on t ro 1) for confirming a non-amplification situation (false negative) due to decomposition and inactivation of the reagent in the composition of the present invention.
- the internal standard can be amplified by the primer of the present invention.
- composition suitable for the detection method of the present invention and containing the various components described above can be mentioned.
- the composition is a suitable type III and chimeric oligonucleotide primer.
- the amplification reaction can be carried out only by adding.
- a composition containing a chimeric oligonucleotide primer suitable for amplification of the amplification target is suitable.
- a composition suitable for the nucleic acid amplification method of the present invention and containing the various components described above.
- the composition can be amplified only by adding an appropriate type II.
- the reaction can be performed.
- a detection probe is included, a target nucleic acid derived from a pathogenic microorganism can be detected in real time.
- the use of the method of the present invention, the composition or the kit for the method makes it possible to compare the conventional Amplicon HCV kit with a measurement range of two orders.
- the measurement range can be extended to three orders.
- the time required for a conventional Amplicon HCV kit is approximately 5 Compared to the time, the present invention can significantly reduce the required time to about 45 minutes. Therefore, it is possible to increase the number of samples that can be processed in one day.
- the kit of the present invention is a kit for detecting a target nucleic acid derived from a pathogenic microorganism, and is not particularly limited, but a probe capable of hybridizing with a target nucleic acid under conditions of pH exceeding pH 7, particularly limited
- the probe contains the probe described in (1) above.
- kits for detecting a tuberculosis bacterium group include Mycobacceteriumutubesirccuolisis, Mycobaccteiumbovios BCG, Mycobaccteriuimafricanum, Mycobatecreimummicoroti, and proprietary and bi
- the kit can also be used for detection of Mycobacterium tuberculosis colonies under pH conditions exceeding pH 7.
- kits of the present invention includes a kit for detecting a phosphorus bacterium.
- the kit is characterized in that it contains a probe capable of specifically detecting Neisse riagon horea e.
- the kit can also be used for detecting phosphate bacteria under alkaline conditions exceeding pH7.
- kits for detecting chlamydia includes a kit for detecting chlamydia.
- the kit is characterized in that it contains a probe capable of specifically detecting Chlamidiattrachomatis.
- the kit can also be used for the detection of chlamydia under alkaline conditions exceeding pH7.
- kits for detecting HCV includes a kit for detecting HCV.
- the kit is characterized by containing a probe capable of specifically detecting HCV.
- the kit can also be used for detecting HCV under alkaline conditions exceeding pH 7.
- the above-mentioned kit may contain a primer as another embodiment. Furthermore, a reagent for a nucleic acid amplification method for amplifying a target gene (DNA polymerase) And a kit containing reagents used for the probe detection reaction, reagents used for extracting nucleic acids from the specimen, and the like.
- the kit is suitable for performing the method for detecting a tuberculosis bacterium group or the like of the present invention simply and promptly.
- the kit can provide test results with high reproducibility and reliability, especially when examining the presence of a tuberculosis bacterium group or the like in a large number of samples.
- it may contain an internal standard (IC; internal 1 control) for live confirmation of false negative 'I "and a probe for detecting the internal standard.
- the internal standard is amplified by the primer of the present invention. be able to.
- the kit is characterized in that it comprises, in packaged form, instructions for the use of the probes, primers, DNA polymerase and endonuclease of the invention.
- commercially available DNA polymerase and / or endonuclease may be selected and used according to the instructions. Further, it may contain a reagent for a reverse transcription reaction when the RNA is of type II.
- the DNA polymerase can be selected from the DNA polymerases described above.
- the end nuclease can be selected from either Pfu-derived RNAse HII or Afu-derived RNAseHII.
- the ⁇ instructions '' are printed materials that describe how to use the kit, for example, how to prepare a reagent solution for strand displacement reaction, recommended reaction conditions, etc.
- the label attached to the kit and the one described on the package containing the kit are included. It also includes information disclosed and provided through electronic media such as the Internet.
- the kit of the present invention may include a reaction buffer containing a bicine, tricine, mouse, phosphate, or Tris buffer component, and a annealing solution.
- DNA polymerase ⁇ RNaseH may be contained.
- it may contain modified deoxyliponucleotides or analogs of deoxynucleotide triphosphates.
- the kit of the present invention provides a kit capable of detecting a target nucleic acid derived from a pathogenic microorganism in real time by appropriately selecting a detection probe. (6) The nucleic acid extraction method of the present invention
- the present invention provides a nucleic acid extraction method for detecting Mycobacterium tuberculosis or the like with high sensitivity.
- nucleic acid extraction from clinical specimens is a delicate and difficult process, from liquid samples such as urine, pleural effusion, cerebrospinal fluid, and blood to dense viscous samples such as pus and sputum, as well as cells and tissues.
- the target is wide even to things.
- the present inventors have studied the above-mentioned various conventional methods and the muramidase, which has been used in the past to produce nucleic acids from the genus Listeria, Lactobaci 11 us, and the genus Streptococcus. Mutanolysin from S trept om ycesglobisporus
- the sample containing M. tuberculosis was treated with muramidase for 30 minutes, treated at 96 ° C for 5 minutes at the next step, and the gene was amplified by the ICAN method to detect M. tuberculosis.
- muramidase for 30 minutes
- treated at 96 ° C for 5 minutes at the next step
- the gene was amplified by the ICAN method to detect M. tuberculosis.
- the above-described series of detection operations can eliminate the inhibitory effect of the components mixed in the nucleic acid extract on the nucleic acid amplification reaction in the conventional method using a surfactant or a chaotropic pick reagent.
- the heat treatment also has a bactericidal effect against tuberculosis bacterium and the like, and has the advantage of preventing infection of tuberculosis bacterium and the like in the laboratory, which has been troublesome for conventional inspectors. Therefore, the invention of this protocol can rapidly, safely and highly sensitively extract DNA of M. tuberculosis and the like.
- the sputum when sputum is used as a sample, the sputum is first processed by a known sputum processing method, NAL C (N-acetyl-L-cysteine) _NaOH method. After the treatment, it is preferable to carry out the above-described nucleic acid extraction method of the present invention. That is, the detection method of the present invention may include a step of treating a sample containing Mycobacterium tuberculosis or the like with muramidase to extract a nucleic acid.
- NAL C N-acetyl-L-cysteine
- the obtained bacterial cells were suspended in 4 ml of 25% sucrose, 50 mM Tris-HCl (pH 8.0), and 0.4 ml of 1 OmgZm 1 Shiojiri lysozyme (manufactured by Nakara Testa Co., Ltd.) ) An aqueous solution was added and reacted at 20 ° C for 1 hour. After completion of the reaction, 24 ml of 15 OmM NaCl, 1 mM EDTA, 2 OmM Tris-HC1 (pH 8.0), 0.2 ml of 2 Omg / m1 proteinase K
- the PH1650 gene (SEQ ID NO: 1) and a part of the genome of Pyrococcus furiosus, which have been partially disclosed, are available at the University of Utah, Utah Genome Center homepage: http: // www. Genome. Utah, edu / sequence, html). As a result, a sequence with a very high homology was found.
- primers 1650 Nde SEQ ID NO: 2
- 165.0 Bam SEQ ID NO: 3
- PCR was carried out in a volume of 100 Z1 using 20 pmol of 1650 Nde and 20 pmo 1 of 1650 Ba as primers.
- DNA poly in PCR As the merase, Takara Ex tack (manufactured by Takara Shuzo) was used according to the attached protocol, and the PCR was performed 30 cycles at 94 ° C for 30 seconds, 55 ° C for 30 seconds, and 72 ° C for 1 minute as one cycle.
- the amplified DNA fragment of about 0.7 kb was digested with NdeI and BamHI (both from Takara Shuzo), and the obtained DNA fragment was digested with NdeI of plasmid vector; pET3a (Novagen). Plasmid p between I and BamHI
- the nucleotide sequence of the inserted DNA fragment of pPFU220 obtained in (2) above was determined by the dideoxy method.
- E. coli HMS174 (manufactured by Novagen)
- E. coli HM S174 (DE3) containing the obtained pPFU220 was transformed at 100 g / m1.
- the cells were inoculated into 2 liters of LB medium containing ampicillin and cultured at 37 ° C for 16 hours with shaking. After completion of the culture, the cells collected by centrifugation were transferred to a 66.
- Om 1 solution buffer [5 OmM Tris-HCl
- the heat-treated supernatant was applied to a RES OUR SEQ column (manufactured by Amersham-Balmacia Biotech) equilibrated with buffer A [5 OmM Tris-HC1 (pH 8.0) ImM EDTA], and then subjected to an FP LC system (Amersham Fanolemasia). Chromatography was performed using Biotech). As a result, the RNAse HII passed through the RE SOURS EQ column.
- the passed RNase HII fraction was applied to a RES OUR SES column (manufactured by Amersham Pharmacia Biotech) equilibrated with buffer A, and the linear concentration of OmM NaC1 was determined using an FP LC system.
- the RNase HII fraction eluted at about 15 OmM NaCl by the gradient was obtained.
- This RNase HII fraction was purified by centrifugation using Centricon 10 (Amicon). The solution was concentrated by filtration, and 250 ⁇ l of the concentrated solution was flattened with 5 OmM Tris-HC1 (pH 8.0) containing 10 OmM NaCl10. ImM EDTA.
- the solution was applied to a 200 gel filtration column (manufactured by Amersham Pharmacia Nanotech) and eluted with the same buffer.
- RNase HII was eluted at a position corresponding to a molecular weight of 17 kDa. This molecular weight corresponds to the case where RNase HII is present as a monomer.
- RNAseHII eluted in this manner was used as a PfuRNaseHII standard.
- RNaseH activity was measured by the following method using the P PuRNaseHHII sample obtained above.
- Amelekajeglobus fulgidus (Archaeoglobus fulgidus, purchased from Germany Che Zamnosch von Microonoreganismen ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ D D D D D D D ⁇ ⁇ ⁇ 8) Suspend in 50 mM Tris-HC1 (pH 8.0) and add 20 ⁇ l of 0.5 ⁇
- the amplified DNA fragment of about 0.6 kb is digested with NdeI and BamHI (both from Takara Shuzo Co., Ltd.), and the obtained DNA fragment is treated with a plasmid vector: TV119Nd (1 ⁇ oI site of pTV1191 ⁇ ). Was converted to an NdeI site) to produce a plasmid pAFU204 which was inserted between NdeI and BamHI.
- the nucleotide sequence of the inserted DNA fragment of pAFU204 obtained in (2) above was determined by the dideoxy method.
- E. coli JM109 was transformed with pAFU204 obtained in (2) above, and the obtained E. coli JM109 containing pAFU204 was inoculated into 2 liters of LB medium containing 100 wg Zml of ampicillin, and incubated at 37 ° C for 16 hours. The cells were cultured with shaking for hours. End of culture After completion, the cells collected by centrifugation were transferred to 37. lm 1 sonication buffer [50111] ⁇ 1 Tris ⁇ [ ⁇ 1 (pH 8.0), 1 mM EDTA, 2 mM phenyl methanesulfonyl fluoride] And sonicated.
- This crushed liquid was centrifuged at 12000 r 1) 111 for 10 minutes, and the obtained supernatant was subjected to a heat treatment at 70 ° C. for 15 minutes. Thereafter, the mixture was centrifuged again at 12000 rpm for 10 minutes, and the supernatant was collected to obtain a heat-treated supernatant of 40.3 ml.
- the heat-treated supernatant was applied to a RES OU RSEQ column (manufactured by Amersham Pharmacia Biotech) equilibrated with buffer A [50 mM Tris-HC1 (pH 8.0), ImM EDTA], and the F PLC system (Amersham Pharmacia Biotech) was used. Chromatography). As a result, RNaseHI I passed through the RESOURSE Q column.
- RNAseHII passed through the RESOURSE S column.
- the RNaseH II fraction passed through 40.Oml was buffered with 50 mM NaC1 in buffer B [50 mM Tris-HC1 (pH 7.0), ImMEDTA] 21 as an external solution, and subjected to 2 hour dialysis three times. Got it.
- the dialyzed enzyme solution (40.2 ml) was applied to a HiTra ph eparin column (manufactured by Amersham Pharmacia Biotech) equilibrated with buffer B containing 5 OmM NaC1. Eluted with a linear gradient of O-550 mM NaCl. As a result, an RNaseHII fraction eluted at about 24 OmM NaC1 was obtained.
- This RNaseHI fraction 7.8 ml was concentrated by ultrafiltration using Centricon-1 10 (manufactured by Amicon), and about 600 1 of the concentrated solution was divided into four portions to give 100 mM NaCl, 0 50 mM Tris-HC1 containing ImM EDTA (pH 7.
- the solution was applied to a Superose 6 gel filtration column (manufactured by Amersham Pharmacia Biotech) equilibrated in step 0), and eluted with the same buffer.
- RNase HI I was located at a position corresponding to a molecular weight of 30.0 kDa. Eluted. This molecular weight corresponds to the case where RNaseHII exists as a monomer. In this way The released RNaseHII was used as an AfuRNaseHII sample.
- the number of cuts of the heat-resistant RNaseH used in the method of the present invention was calculated by the following method.
- the poly (rA) - was prepared poly (dT) dissolved solution.
- 0.5 M EDTA ( ⁇ ) was added to the above reaction solution, and the mixture was reacted at 40 ° C. for 10 minutes, and the absorbance was measured.
- a value (absorbance difference) was obtained by subtracting the absorbance of the control from the absorbance determined by reacting in the absence of EDTA. That is, the concentration of nucleotides released from the poly (rA) -poly (dT) hybrid by the enzymatic reaction was determined from the absorbance difference.
- concentration of nucleotides released from the poly (rA) -poly (dT) hybrid by the enzymatic reaction was determined from the absorbance difference.
- One unit of RNaseH is equivalent to 1 nmol of ribonucleotide released A 26 . was calculated as the amount of the enzyme to be increased in 10 minutes, according to the following equation.
- Polyadelic acid solution Polyadelic acid was diluted to 3 mM with sterile ultrapure water.
- Enzyme diluent Final concentrations of 25 mM Tris-HCl (pH 7.5, 37 ° C), 5 mM 2-mercaptoethanol, 0.5 mM EDTA (pH 7.5, 37 ° C), 3 OmM sodium chloride And 50% glycerol in sterile water.
- Preparation of heat-denatured calf thymus DNA 200 mg of calf thymus DNA was suspended in 100 ml of TE buffer and allowed to swell. The absorbance of the solution at UV 260 nm was measured and diluted with sterile ultrapure water to a concentration of 1 mg / ml. Next, the solution was heated at 100 ° C. for 10 minutes and rapidly cooled in an ice bath.
- reaction solution 501 for total CPM and the reaction solution 501 for plank were prepared by adding 1 ⁇ l of an enzyme diluent instead of the enzyme solution.
- the mixture was kept at 0 ° C for 5 minutes, and then centrifuged at lOOO rpm for 10 minutes. After centrifugation, place 250 ⁇ l of the resulting supernatant in a vial and add Aquasolu 2 ( ⁇ Life 1 Oml was added, and the CP ⁇ was measured with a night body scintillation counter.
- the unit number of each enzyme was calculated by the following formula.
- a specific oligonucleotide probe for detecting the IS6110 gene derived from Mycobacterium tuberculosis was prepared based on the nucleotide sequence described in GenBank Accession No. X 52471. That is, the nucleotide sequence shown in SEQ ID NO: 11 in the sequence listing
- the oligonucleotide probe MTIS-2BF with FITC (fluorescein isothiocyanate) at the end was synthesized using a DNA synthesizer.
- a chimeric oligonucleotide primer was prepared for synthesizing a DNA fragment derived from the Mycobacterium tuberculosis group IS 6110 gene by the ICAN method.
- a forward primer K-F103-3-2 consisting of the nucleotide sequence shown in SEQ ID NO: 15 in the sequence listing, a nucleotide sequence consisting of SEQ ID NO: 16 in the sequence listing, and a biotin at the 5 'end
- a reverse primer K-R113133-2Bio was synthesized by a DNA synthesizer.
- a reaction solution for the ICAN reaction shown in Table 1 was prepared and allowed to stand at 60 ° C. for 30 minutes.
- an ICAN amplification reaction was carried out also by combining the K-F1033-2 / K-R1133-2 primer. After the completion of the reaction, a part of the above reaction solution was subjected to electrophoresis to confirm a target amplified fragment.
- Dissolve streptavidin (manufactured by Nacalai) at a concentration of PBS and add this solution to a 96-well microtiter plate for white light emission detection so as to obtain 15 Oju 1 urenole, and leave at 4 ° C overnight. Then, I fixed it. After discarding the streptavidin solution, a 1% BSA-PBS solution was dispensed to 200 ⁇ l / well and left at 4 ° C for ⁇ to perform blocking. The solution discarded was used as a streptavidin-coated plate in the following experiments.
- Detection of Mycobacterium tuberculosis complex DNA was performed as described above for sputum-derived DNII samples containing 0, 5 and 10 copies of the genome of Mycobacterium tuberculosis complex. As a result, as shown in Table 2, strong luminescence with an S / N ratio of about 300 times was detected even in 5 copies.
- the present invention enables rapid and highly sensitive detection of M. tuberculosis.
- the method for detecting Mycobacterium tuberculosis of the present invention can be suitably used in any of the method for extracting nucleic acid of the present invention and the method using a reagent for yeast Gent. Therefore, the usefulness of the nucleic acid extraction method of the present invention was confirmed in view of the simplicity of the operation method.
- the method of the present invention agreed well with the results of the culture test, but the PCR method detected two cases that were negative in the culture method as false positives, and one case that was positive in the culture method. Detected as false negative.
- the method of the present invention can obtain an accurate inspection result extremely quickly and easily as compared with the conventional method.
- the specificity of the detection method of the present invention for the Mycobacterium tuberculosis group was examined.
- As the genomic DNA 37 strains shown in Table 4 were used.
- each genomic D NA is the copy number was calculated from the OD value, was diluted to 2 X 1 0 7 copies.
- Example 2 (1) Detection of Mycobacterium tuberculosis complex using magnetic beads was examined.
- primers MTIS-2F primer and MTIS-2RBio primer were used.
- the extracted genome derived from the positive sample in Example 2 was diluted with sterile water to prepare a 30-fold, 300-fold, or 3000-fold extract of type II. The reaction was performed as follows.
- the reaction solution was set on a thermal cycler personal set at 60 ° C. in advance and held for 60 minutes. The obtained amplified fragment was automatically detected by Lumino.
- the detection system when the internal standard (IC; internal control) was combined was examined.
- An internal standard was prepared as follows. That is, human genome DNA was designated as type III, and PCR amplification was carried out using the primers of SEQ ID NOS: 17 and 18 in the rooster table. The resulting amplified fragment was purified by a conventional method and inserted into pT7BlueT-vector (Novagen). The plasmid was used as an internal standard. The reaction was carried out under the same conditions as described in Example 3 with the addition of 1, 3, and 10 pg of the above plasmid. 0, 2, and 20 copies were used for the type I M. tuberculosis genome.
- an I C probe (I CF probe) having the base sequence shown in SEQ ID NO: 19 in the sequence listing and having a F ITC label at the 5 ′ end, and a F ITC labeled probe MT ISB F were used.
- I C probe I CF probe
- F ITC labeled probe MT ISB F F ITC labeled probe
- Hybridization buffer (5 X SSC, 1% Triton Xl O O,
- Negative control solution 0.02 ml Mycobacteri um tuberculosis strain and Mycobacteri um bovis BCG strain were detected using the above reagents. We have discovered that it can be specifically detected.
- oligonucleotide probes for detecting Chlamydia cryptic plasmids were constructed. That is, an oligonucleotide probe CT1234 consisting of the nucleotide sequence shown in SEQ ID NO: 20 of the sequence listing and having FITC (fluorescein isothiosinate) attached to its 5 ′ end was synthesized by a DNA synthesizer. In addition, a specific oligonucleotide probe for detecting the cppB gene of the bacterium was prepared.
- an oligonucleotide probe CppB3 consisting of the nucleotide sequence shown in SEQ ID NO: 21 of the sequence listing and having FITC (fluorescein isothiosinate) attached to its 5 'end was synthesized by a DNA synthesizer. .
- DNA fragments derived from Chlamydia cryptic plasmids were combined by the ICAN method.
- a chimeric oligonucleotide primer was prepared. That is, based on the base sequence of the chlamydia talibic plasmid shown in SEQ ID NO: 22 in the sequence listing, a foreprimer consisting of the base sequence shown in SEQ ID NOS: 23 and 24 in the sequence listing.
- a chimeric oligonucleotide primer was prepared for synthesizing a DNA fragment derived from the phosphobacterium cppB gene by the ICAN method. That is, based on the base sequence of the Chlamydia talibutic 'plasmid shown in SEQ ID NO: 27 in the sequence listing, a forward primer pJDBF-I comprising the base sequence shown in SEQ ID NO: 28 in the sequence listing Reverse primers pJDBR-3Bio having the base sequence shown in SEQ ID NO: 29 and having a biotin at the 5 'end were synthesized by a DNA synthesizer.
- Dissolve streptavidin (manufactured by Nacalai) at a concentration of 2 / ig / ml in PBS, and add this solution to a 96-well microtiter plate for white luminescence detection at a concentration of 15 ⁇ l / well. It was left undisturbed at 4 ° C for 1 hour and fixed. After discarding the streptavidin solution, a 1% BSA-PBS solution was dispensed so as to be 200/1 / well, and allowed to stand at 4 ° C for blocking. The discarded solution was used as a streptavidin-coated plate in the following experiments.
- Hybridization buffer was added to the above streptavidin-coated plate.
- wash buffer 25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% BSA, 0.05% Wash the well twice with Tween 20]. Then, a peroxidase-labeled anti-FITC ⁇ egret antibody (Chemicon ) was added to a hybridization buffer at a concentration of 2 g Zm 1, and the mixture was allowed to react at room temperature for 20 minutes. After the reaction, discard the solution, wash the wells 4 times with 200 ⁇ l / well of wash buffer,
- Chlamydia DNA detection was performed on DNA samples containing the chlamydia genome equivalent to 0, 100 and 100 copies as described above. As a result, as shown in Table 8, even at 10 copies, strong emission of about 30 times in SZN ratio was detected. In addition, the detection of the phospho-DNA was performed on the DNA sample containing the phospho-genome corresponding to 0, 10 and 100 copies as described above. As a result, as shown in Table 9, even at 100 copies, light emission with a strong S / N ratio of about 300 times could be detected. Table 8
- the present invention enables rapid and highly sensitive inspection of chlamydia and phosphobacterium.
- HCV-F and HCV-R1 chimeric oligonucleotide primers having the nucleotide sequences of SEQ ID NOs: 30 and 31 in the sequence listing and the bases of SEQ ID NOs: 32 and 33 in the sequence listing Oligonucleotide primers having a sequence for a reverse transcription reaction were synthesized. Furthermore, oligonucleotide probes having the nucleotide sequences shown in SEQ ID NOS: 34 and 35 in the rooster list were synthesized.
- TAMRA (manufactured by N, N, ⁇ ', N, -tetramethyl-6-carboxy-rhodamine ABI) was prepared at the 5, terminal of the above oligonucleotide probe by an automatic DNA synthesizer and used as a fluorescent-labeled probe. .
- the copy number of the HCV-RNA positive serum obtained with informed consent was calculated using the Amplicon HCV moter kit (Roche), and this was used as the sample diluent supplied with the kit, and 1 copy from 1 x 10 7 copies. A 10-fold dilution series was prepared up to 71 and used as HCV-RNA.
- CDNA was synthesized from the HCV-RNA prepared in the above (2) using the reverse transcription reaction primer prepared in the above (1), and First-sttranddcDNA SynthesEsKit (manufactured by Takara Shuzo).
- Table 10 shows the composition of the reaction solution per tube.
- the above reaction solution 471 was added per reaction tube, 3 ⁇ l of the cD ⁇ solution prepared in (4) was added thereto, and the mixture was kept at 56 ° C for 30 minutes. After completion of the reaction, apply the fluorescent labeling probe prepared in (1) above to this reaction mixture so that the final concentration becomes 300 nM, treat at 98 ° C for 2 minutes, and cool to 25 ° C by cooling with water. , Held.
- the fluorescence intensity of the reaction solution was measured with a fluorescence detector, fluoroscan (manufactured by Lavao Systems). Furthermore, as a control, the same sample was used for the measurement using an amplicor HCV kit (manufactured by Roche) by a commercially available PCR method.
- Figure 1 shows the results.
- Figure 1 is a graph showing the change in fluorescence intensity when various HCV-RNA concentrations were measured and a comparison of the measurement range with the conventional method.
- the left vertical axis shows the OD450 value, and the right vertical axis shows the fluorescence intensity (SN). Ratio) and the horizontal axis indicates the amount of HCV-RNA.
- the black squares in Fig. 1 show the results obtained by the method of the present invention, and the black circles show the results obtained using the Amplicor HCV kit.
- the fluorescence intensity (SN ratio) increased as the number of HCV-RNA copies increased.
- the time required for the HCV detection method of the present invention was 45 minutes.
- the time required for the control Amplicor HCV kit was about 5 hours.
- the detection range of HCV-RNA as shown in Fig. Although increasing is in accordance with increase in the number of copies of the V- RNA, measurement range is 2 O over Zehnder, in 1 0 5 or more copies, it was confirmed that there is no quantitative properties.
- the method of the present invention has a wide detection range of three orders.
- the method of the present invention was excellent in terms of simplicity and rapidity, and it was confirmed that the method was suitable for processing multiple samples.
- RNA was prepared from HCV-RNA extraction reagent (Roche) attached to Amplicor HCV kit from 100 ⁇ ⁇ of each of 28 serums of HCV patients from which informed consent was obtained.
- Example 1 HCV-RN ⁇ was amplified by the same method as described in (3) and (4), and used for the detection method of the present invention.
- the cut-off value was defined as the average value of the fluorescence intensity of 10 negative controls + 3 SD (three times the standard deviation) performed on the control sample containing no HCV-RNA. Specimens showing a fluorescence intensity exceeding were regarded as positive.
- the same sample was measured with a commercially available Amplicor HCV kit, and positive / negative was determined according to the instruction manual of the kit. Table 11 shows a comparison between the results of the detection method of the present invention and the results of the conventional Amplicon HCV kit.
- Negative 0 case 10 case As shown in Table 11, it was confirmed that the measurement result by the method of the present invention correlated well with the result obtained by the conventional method. In addition, it was confirmed that the method of the present invention can measure with high sensitivity, quickly and easily, compared to the conventional method.
- the present invention it is possible to measure pathogenic microorganisms with high sensitivity, high specificity, and quickly and easily.
- a method, a primer, a probe, and a kit that can process a large number of samples in a limited time without using special equipment are provided.
- SEQ ID NO: 2 PCR primer 1650Nde for cloning a gene encoding a polypeptide having a RNaseHII activity from Pyrococcus furiosus
- SEQ ID NO: 3 PCR primer 1650Bam for cloning a gene encoding a polypeptide having a RNaseHII activity from Pyrococcus furiosus
- SEQ ID NO: 7 PCR primer AfuNde for cloning a gene encoding a
- polypeptide having a RNaseHII activity from Archaeoglobus fulgidus having a RNaseHII activity from Archaeoglobus fulgidus
- SEQ ID NO: 8 PCR primer AfuBam for cloning a gene encoding a
- polypeptide having a RNaseHII activity from Archaeoglobus fulgidus having a RNaseHII activity from Archaeoglobus fulgidus
- SEQ ID NO: 11 Oligonucleotide probe to detect the DNA derived from Mycobacterium tuberculosis
- SEQ ID NO: 13 Chymeric oligonucleotide primer to amplify the DNA fragment of IS6110 gene derived from Mycobacterium
- nucleotides 16 to 18 are ribonucleotides- other nucleotides are deoxyribonucleotides
- SEQ ID NO: 14 Chymeric oligonucleotide primer to amplify the DNA fragment of IS6110 gene derived from Mycobacterium
- nucleotides 19 to 21 are ribonucleotides other nucleotides are deoxyribonucleotides
- SEQ ID NO: 15 Chimeric oligonucleotide primer to amplify the DNA fragment of IS6110 gene derived from Mycobacterium
- nucleotides 19 to 21 are ribonucleotides— other nucleotides are deoxyribonucleotides
- SEQ ID NO: 16 Chimeric oligonucleotide primer to amplify the DNA fragment of ISollO gene derived from Mycobacterium
- nucleotides 20 to 22 are; ribonucleotides— other nucleotides are deoxyribonucleotides "
- SEQ ID NO: 17 Oligonucleotide primer C4-MT2F— S100 to amplify the DNA fragment of metaroprotease gene from human
- SEQ ID NO: 18 Oligonucleotide primer C4— MT2R- A to amplify the DNA fragment of metaroprotease gene from human
- SEQ ID NO: 19 Oligonucleotide probe to detect the internal control DNA
- SEQ ID NO: 20 Oligonucleotide probe CT1234 to detect the Chramydia criptic plasmid
- SEQ ID N0: 21 Oligonucleotide probe CppB3 to detect Neisseria gonorrhoeae cppB gene
- SEQ ID NO: 23 Chimeric oligonucleotide primer to amplify the DNA fragment of Chramydia criptic plasmid. ⁇ nucleotides 20 to 22 are ribonucleotides-other nucleotides are deoxyribonucleotides'
- SEQ ID NO: 24 Chimeric oligonucleotide primer to amplify the DNA fragment of Chramydia criptic plasmid. "Nucleotides 20 to 22 are ribonucleot ides-other nucleotides are deoxyribonucleotides"
- SEQ ID NO: 25 Chimeric oligonucleotide primer to amplify the DNA fragment of Chramydia criptic plasmid, "nucleotides 20 to 22 are ribonucleotides-other nucleotides are deoxyribonucleotides"
- SEQ ID NO: 26 Chimeric oligonucleotide primer to amplify the DNA fragment of Chramydia criptic plasmid. "Nucleotides 20 to 22 are ribonucleotides-other nucleotides are deoxyribonucleotides"
- SEQ ID NO: 28 Chimeric oligonucleotide primer to amplify the DNA fragment of Neisseria gonorrhoeae cppB gene, "nucleotides 18 to 20 are ribonucleot ides-other nucleotides are deoxyribonucleotides"
- SEQ ID NO: 29 Chimeric oligonucleotide primer to amplify the DNA fragment of Neisseria gonorrhoeae cppB gene, "nucleotides 15 to 17 are ribonucleotides-other nucleotides are deoxyribonuc ⁇ eotides"
- SEQ ID No: 30 Designed chimeric oligonucleotide primer designated as HCV- F to amplify a portion of HCV. "Nucleotides 19 to 21 are
- SEQ ID No: 31 Designed chimeric oligonucleotide primer designated as
- Ribonucleotides-other nucleotides are deoxyribonucleotides
- SEQ ID No: 32 Designed oligonucleotide primer to synthsize cDNA of HCV
- SEQ ID No: 33 Designed oligonucleotide primer to synthsize cDNA of HCV
- SEQ ID No: 34 Designed oligonucleotide probe to detect a DNA fragment amplifying a portion of HCV
- SEQ ID No: 35 Designed oligonucleotide probe to detect a DNA fragment amplifying a portion of HCV
- SEQ ID No: 36 Oligonucleotide primer to amplify the DNA fragment of
- SEQ ID No: 37 Oligonucleotide primer to amplify the DNA fragment of
- SEQ ID No: 41 Primer area to amplify a portion of HCV
- SEQ ID No: 42 Primer area to amplify a portion of HCV
- SEQ ID No: 43 Probe area to detect a DNA fragment amplifying a portion of HCV
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/451,882 US20040185455A1 (en) | 2000-12-26 | 2001-12-26 | Method of detecting pathogenic microorganism |
JP2002553522A JP4092201B2 (ja) | 2000-12-26 | 2001-12-26 | 病原微生物の検出方法 |
KR10-2003-7008086A KR20030064420A (ko) | 2000-12-26 | 2001-12-26 | 병원성 미생물 검출 방법 |
EP01272324A EP1347060A4 (en) | 2000-12-26 | 2001-12-26 | METHOD FOR DETECTION OF A PATHOGENIC MICROORGANISM |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-396222 | 2000-12-26 | ||
JP2000396321 | 2000-12-26 | ||
JP2000-396321 | 2000-12-26 | ||
JP2000396222 | 2000-12-26 | ||
JP2001199552 | 2001-06-29 | ||
JP2001-199552 | 2001-06-29 | ||
JP2001278920 | 2001-09-13 | ||
JP2001-278920 | 2001-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002052043A1 true WO2002052043A1 (fr) | 2002-07-04 |
Family
ID=27481923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/011422 WO2002052043A1 (fr) | 2000-12-26 | 2001-12-26 | Procede de detection d'un micro-organisme pathogene |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040185455A1 (ja) |
EP (1) | EP1347060A4 (ja) |
JP (1) | JP4092201B2 (ja) |
KR (1) | KR20030064420A (ja) |
CN (1) | CN1491285A (ja) |
TW (1) | TWI311154B (ja) |
WO (1) | WO2002052043A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1598431A1 (en) * | 2003-02-27 | 2005-11-23 | ARKRAY, Inc. | Method of detecting chlamydia trachomatis and kit therefor |
KR100532664B1 (ko) * | 2002-09-09 | 2005-12-02 | 주식회사 바이오메드랩 | 클라미디아 트라코마티스 탐지용 프로브, 이를 포함하는 클라미디아 트라코마티스 탐지용 키트, 및 이를 이용한 클라미디아 트라코마티스의 탐지방법 |
EP1944368A1 (en) | 2007-01-15 | 2008-07-16 | Konica Minolta Medical & Graphic, Inc. | Nucleic acid isolation method by heating on magnetic support |
JP2008538910A (ja) * | 2005-04-29 | 2008-11-13 | ミリポア・コーポレイション | フィルター上の微生物の検出及びキャラクタリゼーション方法 |
CN101302556B (zh) * | 2002-12-18 | 2011-05-25 | 生物技术部 | 编码结核分枝杆菌组蛋白样蛋白质的hupB基因的鉴定 |
CN103060452A (zh) * | 2013-01-10 | 2013-04-24 | 湖南圣湘生物科技有限公司 | 沙眼衣原体ct检测试剂盒 |
JP2013542712A (ja) * | 2010-07-29 | 2013-11-28 | エフ.ホフマン−ラ ロシュ アーゲー | 微生物核酸の定性的および定量的検出 |
JP2014510926A (ja) * | 2011-04-07 | 2014-05-01 | ザ スクリップス リサーチ インスティテュート | 細胞巨大分子の発現を調節する化合物のハイスループットスクリーニング |
CN105779650A (zh) * | 2016-04-01 | 2016-07-20 | 中国农业科学院哈尔滨兽医研究所 | 用于鉴别伪狂犬病病毒株的三重荧光定量pcr的引物、探针和试剂盒 |
JP2016187338A (ja) * | 2010-07-29 | 2016-11-04 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 微生物核酸の定性的および定量的検出 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2375406T3 (es) | 2004-04-26 | 2012-02-29 | Wako Pure Chemical Industries, Ltd. | Sonda y cebador para la detección de bacilos tuberculosos, y procedimiento para la detección de bacilos tuberculosos humanos con el uso de los mismos. |
US20060094004A1 (en) * | 2004-10-28 | 2006-05-04 | Akihisa Nakajima | Micro-reactor, biological material inspection device, and microanalysis system |
US7842794B2 (en) * | 2004-12-17 | 2010-11-30 | Roche Molecular Systems, Inc. | Reagents and methods for detecting Neisseria gonorrhoeae |
EP2351857B1 (en) * | 2005-02-17 | 2014-10-29 | TrovaGene, Inc. | Compositions and methods for detecting pathogen specific nucleic acids in urine |
KR20080066993A (ko) * | 2005-11-07 | 2008-07-17 | 지멘스 헬쓰케어 다이아그노스틱스 인크. | 클라미디아 트라코마티스 특이적 올리고뉴클레오티드 서열 |
CN101191145B (zh) * | 2006-11-28 | 2010-05-26 | 薛树仁 | 一种高效检测临床样品中结核分支杆菌复合体的方法 |
US20090230300A1 (en) * | 2007-10-19 | 2009-09-17 | Jose Miguel Trevejo | Rapid detection of volatile organic compounds for identification of bacteria in a sample |
CN101168779B (zh) * | 2007-11-06 | 2010-07-21 | 深圳国际旅行卫生保健中心 | 一种检测结核杆菌的试剂盒及其专用探针与引物 |
US8900807B2 (en) | 2008-02-25 | 2014-12-02 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Composition and methods for rapid detection of HIV by loop-mediated isothermal amplification (LAMP) |
CN101285062B (zh) * | 2008-04-29 | 2011-07-20 | 博奥生物有限公司 | 一种从痰中提取细菌核酸的方法、试剂盒及其应用 |
WO2010030049A1 (en) * | 2008-09-12 | 2010-03-18 | Lg Life Sciences, Ltd. | Composition for detection of m. tuberculosis complex or mycobacteria genus and simultaneous detection method for m. tuberculosis complex and mycobacteria genus with multiplex real time pcr using the same |
WO2010126856A1 (en) * | 2009-04-27 | 2010-11-04 | The Charles Stark Draper Laboratory, Inc. | Rapid detection of volatile organic compounds for identification of mycobacterium tuberculosis in a sample |
KR101158647B1 (ko) * | 2010-05-27 | 2012-06-26 | 울산대학교 산학협력단 | 이중 실시간 중합효소연쇄반응법과 융해곡선분석을 이용하는 결핵균과 항산성비결핵균의 검출 방법 |
US8877464B2 (en) | 2010-07-29 | 2014-11-04 | Roche Molecular Systems, Inc. | Qualitative and quantitative detection of microbial nucleic acids |
JP2013153709A (ja) * | 2012-01-31 | 2013-08-15 | Fujirebio Inc | 等温核酸増幅反応における検出シグナルの補正方法 |
EP2970950B1 (en) * | 2013-03-14 | 2019-08-14 | Wm. Wrigley Jr. Company | Methods of detecting and quantifying nucleic acids within malleable polymers |
EP2925915A4 (en) * | 2013-03-15 | 2016-09-07 | Egenomics Inc | SYSTEM AND METHOD FOR DETERMINING THE RECONCILIATION |
WO2016039377A1 (ja) | 2014-09-11 | 2016-03-17 | タカラバイオ株式会社 | 耐熱性のミスマッチエンドヌクレアーゼの利用方法 |
KR101961642B1 (ko) * | 2016-04-25 | 2019-03-25 | (주)진매트릭스 | 절단된 상보적인 태그 절편을 이용한 표적 핵산 서열 검출 방법 및 그 조성물 |
CN105907861A (zh) * | 2016-05-05 | 2016-08-31 | 广州金域医学检验中心有限公司 | 一种用于分枝杆菌快速检测与分型的引物及方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4957858A (en) * | 1986-04-16 | 1990-09-18 | The Salk Instute For Biological Studies | Replicative RNA reporter systems |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
CA1340807C (en) * | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
WO1990001564A1 (en) * | 1988-08-09 | 1990-02-22 | Microprobe Corporation | Methods for multiple target analyses through nucleic acid hybridization |
FR2663033B1 (fr) * | 1990-06-08 | 1992-09-04 | Pasteur Institut | Detection specifique du mycobacterium tuberculosis. |
US5256536A (en) * | 1990-11-09 | 1993-10-26 | Syntex (U.S.A.) Inc. | Nucleotide probe for Neisseria gonrrhoeae |
US5455166A (en) * | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US5470723A (en) * | 1993-05-05 | 1995-11-28 | Becton, Dickinson And Company | Detection of mycobacteria by multiplex nucleic acid amplification |
WO1995025180A1 (en) * | 1994-03-16 | 1995-09-21 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
US5631130A (en) * | 1994-05-13 | 1997-05-20 | Abbott Laboratories | Materials and methods for the detection of Mycobacterium tuberculosis |
FR2737223B1 (fr) * | 1995-07-24 | 1997-09-12 | Bio Merieux | Procede d'amplification de sequences d'acide nucleique par deplacement, a l'aide d'amorces chimeres |
US5731150A (en) * | 1995-11-01 | 1998-03-24 | Chiron Diagnostic Corporation | IS6110 based molecular detection of mycobacterium tuberculosis |
GB9717061D0 (en) * | 1997-08-13 | 1997-10-15 | Tepnel Medical Ltd | Amplification of nucleic acids |
EP1167524B1 (en) * | 1999-03-19 | 2007-05-16 | Takara Bio Inc. | Method for amplifying a nucleic acid sequence employing a chimeric primer |
-
2001
- 2001-12-26 JP JP2002553522A patent/JP4092201B2/ja not_active Expired - Fee Related
- 2001-12-26 CN CNA018227740A patent/CN1491285A/zh active Pending
- 2001-12-26 WO PCT/JP2001/011422 patent/WO2002052043A1/ja not_active Application Discontinuation
- 2001-12-26 KR KR10-2003-7008086A patent/KR20030064420A/ko not_active Application Discontinuation
- 2001-12-26 US US10/451,882 patent/US20040185455A1/en not_active Abandoned
- 2001-12-26 TW TW090132333A patent/TWI311154B/zh active
- 2001-12-26 EP EP01272324A patent/EP1347060A4/en not_active Withdrawn
Non-Patent Citations (5)
Title |
---|
PETER W.M. HERMANS ET AL.: "Insertion element IS987 from mycobacterium bovis BDG is located in a hot-spot integration region for insertion elements in mycobacterium tuberculosis complex strains", INFECTION AND IMMUNITY, vol. 59, no. 8, August 1991 (1991-08-01), pages 2695 - 2705, XP002905349 * |
R.A. MCADAM ET AL.: "Characterization of a mycobacterium tuberculosis insertion sequence belonging to the IS3 family", MOLEUCLAR MICROBIOLOGY, vol. 4, no. 9, 1990, pages 1607 - 1613, XP002950346 * |
See also references of EP1347060A4 * |
VAN EMBDEN ET AL.: "Genetic variation and evolutionary origin of the direct repeat locus of mycobacterium tuberculosis complex bacteria", JOURNAL OF BACTERIOLOGY, vol. 182, no. 9, May 2000 (2000-05-01), pages 2393 - 2401, XP002950348 * |
Z. FANG ET AL.: "IS6110-mediated deletions of wild-type chromosomes of mycobacterium tuberculosis", JOURNAL OF BACTERIOLOGY, vol. 181, no. 3, February 1999 (1999-02-01), pages 1014 - 1020, XP002905347 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100532664B1 (ko) * | 2002-09-09 | 2005-12-02 | 주식회사 바이오메드랩 | 클라미디아 트라코마티스 탐지용 프로브, 이를 포함하는 클라미디아 트라코마티스 탐지용 키트, 및 이를 이용한 클라미디아 트라코마티스의 탐지방법 |
CN101302556B (zh) * | 2002-12-18 | 2011-05-25 | 生物技术部 | 编码结核分枝杆菌组蛋白样蛋白质的hupB基因的鉴定 |
EP1598431A4 (en) * | 2003-02-27 | 2006-08-16 | Arkray Inc | PROCESS FOR DETECTING CHLAMYDIA TRACHOMATIS AND KIT THEREFOR |
EP1598431A1 (en) * | 2003-02-27 | 2005-11-23 | ARKRAY, Inc. | Method of detecting chlamydia trachomatis and kit therefor |
US7521183B2 (en) | 2003-02-27 | 2009-04-21 | Arkray, Inc. | Method for detecting Chlamydia trachomatis and kit therefor |
JP2008538910A (ja) * | 2005-04-29 | 2008-11-13 | ミリポア・コーポレイション | フィルター上の微生物の検出及びキャラクタリゼーション方法 |
EP1944368A1 (en) | 2007-01-15 | 2008-07-16 | Konica Minolta Medical & Graphic, Inc. | Nucleic acid isolation method by heating on magnetic support |
JP2013542712A (ja) * | 2010-07-29 | 2013-11-28 | エフ.ホフマン−ラ ロシュ アーゲー | 微生物核酸の定性的および定量的検出 |
JP2016187338A (ja) * | 2010-07-29 | 2016-11-04 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 微生物核酸の定性的および定量的検出 |
JP2014510926A (ja) * | 2011-04-07 | 2014-05-01 | ザ スクリップス リサーチ インスティテュート | 細胞巨大分子の発現を調節する化合物のハイスループットスクリーニング |
CN103060452A (zh) * | 2013-01-10 | 2013-04-24 | 湖南圣湘生物科技有限公司 | 沙眼衣原体ct检测试剂盒 |
CN103060452B (zh) * | 2013-01-10 | 2014-03-05 | 湖南圣湘生物科技有限公司 | 沙眼衣原体ct检测试剂盒 |
CN105779650A (zh) * | 2016-04-01 | 2016-07-20 | 中国农业科学院哈尔滨兽医研究所 | 用于鉴别伪狂犬病病毒株的三重荧光定量pcr的引物、探针和试剂盒 |
CN105779650B (zh) * | 2016-04-01 | 2019-09-24 | 中国农业科学院哈尔滨兽医研究所 | 用于鉴别伪狂犬病病毒株的三重荧光定量pcr的引物、探针和试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
KR20030064420A (ko) | 2003-07-31 |
EP1347060A1 (en) | 2003-09-24 |
TWI311154B (en) | 2009-06-21 |
JP4092201B2 (ja) | 2008-05-28 |
US20040185455A1 (en) | 2004-09-23 |
JPWO2002052043A1 (ja) | 2004-04-30 |
EP1347060A4 (en) | 2004-08-18 |
CN1491285A (zh) | 2004-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002052043A1 (fr) | Procede de detection d'un micro-organisme pathogene | |
JP6970268B2 (ja) | 細菌核酸を検出し細菌性膣炎を診断するための方法および組成物 | |
JP7141488B2 (ja) | マイコプラズマ・ジェニタリウムを検出するための組成物と方法 | |
JP5986043B2 (ja) | クラミジア・トラコマチスを検出するためのプライマー及びプローブ配列 | |
US9458513B2 (en) | Primer and probe for detecting chlamydia trachomatis, and method for detecting chlamydia trachomatis using same | |
JP5254016B2 (ja) | 結核の診断のための核酸標的としてのrd9およびis6110の使用、ならびにマルチプレックス−コンプライアントis6110およびrd9標的の提供 | |
Whiley et al. | A real-time PCR assay for the detection of Neisseria gonorrhoeae by LightCycler | |
JP2011050401A (ja) | 核酸の迅速な検出方法 | |
US20150299780A1 (en) | Compositions and methods for detection of clostridium difficile | |
JP4176134B2 (ja) | 病原微生物の検出方法 | |
KR20100083133A (ko) | 레지오넬라속균 rRNA 증폭용 프라이머, 검출방법 및 검출 키트 | |
US9234248B2 (en) | Simultaneous quantitative multiple primer detection of Clostridium difficile | |
JP2010536343A (ja) | 薬剤耐性菌検出方法 | |
US8206930B2 (en) | Compositions and methods for detecting Borrelia afzelii | |
JP6867369B2 (ja) | 結核菌検出のための組成物および方法 | |
Chaudhry et al. | Multiplex polymerase chain reaction assay for the detection of Neisseria gonorrhoeae in urogenital specimens | |
JP2017521083A (ja) | リステリア・モノサイトゲネス(Listeria monocytogenes)を検出するための配列およびこの配列の使用 | |
JP2013055947A (ja) | 結核の診断のための核酸標的としてのrd9およびis6110の使用、ならびにマルチプレックス−コンプライアントis6110およびrd9標的の提供 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002553522 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037008086 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001272324 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10451882 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037008086 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018227740 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001272324 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001272324 Country of ref document: EP |